• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov27
Intellia Therapeutics Receives 'Hold' Rating from 24 Firms
08:47
Nov14
Intellia Therapeutics Inc reports Q3 2025 financial results
04:16
Nov13
Multiple Firms Have Different Ratings and Price Targets for Intellia Therapeutics
13:54
Nov11
Evercore ISI Analyst Downgrades Intellia Therapeutics Rating
09:42
Nov10
Intellia Therapeutics announces positive phase 1 data for nex-z in heart disease patients
20:17
Nov8
Intellia Therapeutics presents positive data for hereditary angioedema treatment
22:16

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 13.78 M, Net Income -101.32 M, EPS -0.9195

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 14.25 M, Net Income -101.26 M, EPS -0.9761

May8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 16.63 M, Net Income -114.33 M, EPS -1.1046

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
HYNE
14.000
+40.00%
+4.000
ASTX
46.070
+36.50%
+12.320
View More